Table 1.

Baseline characteristics of treated patients (FAS).

Characteristic	1 mg/kg Q3W	3 mg/kg Q3W	10 mg/kg Q3W	200 mg Q3W	All patients
Number of patients	6	8	6	10	30
Age, years
Median	64.5	49.5	47.5	55.5	54
Range	35–72	24–66	36–61	27–68	24–72
Sex
Male	1 (16.7)	7 (87.5)	3 (50.0)	6 (60.0)	17 (56.7)
Female	5 (83.3)	1 (12.5)	3 (50.0)	4 (40.0)	13 (43.3)
ECOG performance status
0	0	0	0	0	0
1	6 (100.0)	8 (100.0)	6 (100.0)	10 (100.0)	30 (100.0)
Prior surgery, n (%)	4 (66.7)	8 (100.0)	5 (83.3)	7 (70.0)	24 (80.0)
Tumor type, n (%)
Colorectal cancer	1 (16.6)	1 (12.5)	2 (33.3)	2 (20.0)	6 (20.0)
Breast cancer	3 (50.0)	0	1 (16.6)	2 (20.0)	6 (20.0)
Esophageal cancer	1 (16.6)	2 (25.0)	0	0	3 (10.0)
Pancreatic cancer	0	0	0	2 (20.0)	2 (6.7)
Soft tissue sarcoma	0	2 (25.0)	0	0	2 (6.7)
Neuroendocrine tumor	0	0	1 (16.6)	1 (10.0)	2 (6.7)
Lung cancer	0	0	2 (33.3)	0	2 (6.7)
Gastric cancer	1 (16.6)	0	0	0	1 (3.3)
Cecum cancer	0	0	0	1 (10.0)	1 (3.3)
Thymic cancer	0	0	1 (16.6)	0	1 (3.3)
Kidney cancer	0	1 (12.5)	0	0	1 (3.3)
Ovarian cancer	0	0	1 (16.6)	0	1 (3.3)
Cholangiocarcinoma	0	1 (12.5)	0	0	1 (3.3)
Melanoma	0	1 (12.5)	0	0	1 (3.3)

ECOG,; Eastern Cooperative Oncology Group; FAS, full analysis set; n, number of patients; Q3W, every 3 weeks.